Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
BioMarin Pharmaceutical Community
NasdaqGS:BMRN Community
2
Narratives
written by author
0
Comments
on narratives written by author
36
Fair Values set
on narratives written by author
Community Investing Ideas
BioMarin Pharmaceutical
Popular
Undervalued
Overvalued
BioMarin Pharmaceutical
AN
AnalystHighTarget
Consensus Narrative from 26 Analysts
Aging Global Demographics And Pipelines Will Expand Rare Therapies
Key Takeaways VOXZOGO's unique position, diagnosis initiatives, and international expansion are set to drive prolonged outsized sales and margin growth well beyond current expectations. Pipeline innovation, cost leverage, and savvy acquisitions position BioMarin for sustained margin expansion, new revenue streams, and enhanced long-term earnings growth.
View narrative
US$122.00
FV
52.2% undervalued
intrinsic discount
11.35%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
BioMarin Pharmaceutical
AN
AnalystConsensusTarget
Consensus Narrative from 26 Analysts
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Key Takeaways Expanding global demand, new therapies, and strategic acquisitions strengthen BioMarin's revenue growth, market reach, and future pipeline potential. Operational efficiency, disciplined cost management, and regulatory advantages support sustained profitability and long-term margin stability.
View narrative
US$97.62
FV
40.3% undervalued
intrinsic discount
7.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
26
users have followed this narrative
about 3 hours ago
author updated this narrative
Your Valuation for
BMRN
BMRN
BioMarin Pharmaceutical
Your Fair Value
US$
Current Price
US$58.30
4.7% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-524m
4b
2015
2018
2021
2024
2025
2027
2030
Revenue US$4.2b
Earnings US$909.0m
Advanced
Set Fair Value